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Abstract
Background: With the advent of second-generation sequencing, the expression of gene transcripts can be digitally
measured with high accuracy. The purpose of this study was to systematically profile the expression of both mRNA and
miRNA genes in clear cell renal cell carcinoma (ccRCC) using massively parallel sequencing technology.
Methodology: The expression of mRNAs and miRNAs were analyzed in tumor tissues and matched normal adjacent tissues
obtained from 10 ccRCC patients without distant metastases. In a prevalence screen, some of the most interesting results
were validated in a large cohort of ccRCC patients.
Principal Findings: A total of 404 miRNAs and 9,799 mRNAs were detected to be differentially expressed in the 10 ccRCC
patients. We also identified 56 novel miRNA candidates in at least two samples. In addition to confirming that canonical
cancer genes and miRNAs (including VEGFA, DUSP9 and ERBB4; miR-210, miR-184 and miR-206) play pivotal roles in ccRCC
development, promising novel candidates (such as PNCK and miR-122) without previous annotation in ccRCC
carcinogenesis were also discovered in this study. Pathways controlling cell fates (e.g., cell cycle and apoptosis pathways)
and cell communication (e.g., focal adhesion and ECM-receptor interaction) were found to be significantly more likely to be
disrupted in ccRCC. Additionally, the results of the prevalence screen revealed that the expression of a miRNA gene cluster
located on Xq27.3 was consistently downregulated in at least 76.7% of ,50 ccRCC patients.
Conclusions: Our study provided a two-dimensional map of the mRNA and miRNA expression profiles of ccRCC using deep
sequencing technology. Our results indicate that the phenotypic status of ccRCC is characterized by a loss of normal renal
function, downregulation of metabolic genes, and upregulation of many signal transduction genes in key pathways.
Furthermore, it can be concluded that downregulation of miRNA genes clustered on Xq27.3 is associated with ccRCC.
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Introduction
As the most common type of kidney cancer in adults, renal cell
carcinoma (RCC) is responsible for approximately 90% of all cases
[1]. RCC is a heterogeneous disease consisting of a number of
different subtypes of cancers originating in this organ [2]. Clear
cell renal cell carcinoma (ccRCC) accounts for the vast majority
(,70%) of RCC [3]. The five-year survival rates of RCC patients
decline considerably as the disease progresses from a localized,
regional tumor to distantly metastatic cancer [4].
Despite the high incidence of this type of malignancy in
populations of different ethnicities throughout the world, the
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e15224precise pathogenic mechanisms underlying ccRCC have not been
clearly elucidated. Environmental factors, such as cigarette
smoking, have been suggested to be associated with increased
susceptibility for renal cancer in over 35% of male patients [5],
other risk factors include obesity, hypertension, and acquired
cystic kidney disease is associated with end-stage renal disease [6].
Molecular studies have identified several genes that are causally
implicated in the carcinogenesis of ccRCC, including von Hippel-
Lindau (VHL) [7], hypoxia-inducible factor-1a (HIF1a) [8],
vascular endothelial growth factor (VEGF), and epidermal growth
factor receptor (EGFR) [9]. Recently, various genome-wide gene
expression profiling studies using microarray-based approaches
have provided us with abundant information on the phenotypic
characteristics of ccRCC [10,11,12]. Nevertheless, few gene
expression (profiling) studies have been focused on the mechanisms
that drive acquiring the malignancy of ccRCC.
MicroRNA (miRNA) is an important class of small non-coding
RNAs that can regulate the expression of protein-coding genes
through various mechanisms, including targeted mRNA degrada-
tion and translational inhibition [13,14]. Mutated or abnormally
expressed miRNAs have been identified as oncogenes or tumor
suppressors in many human cancers [15], including RCC
[10,12,16]. However, no consistent conclusion could be drawn
from most of the previous microarray-based studies due to the
limitations of inter-platform differences and the relatively small
sample sizes investigated [10,12,17,18]. With the advent of
second-generation sequencing technology, the expression level of
both miRNAs and mRNAs can be reliably and accurately
quantified on whole-genome scale [19]. Additionally, novel
miRNAs and mRNAs without previous annotation in public
databases can also be discovered with these sequencing platforms
[20].
In this report, we present an integrative analysis of digital gene
expression (DGE) profiling of both mRNAs and miRNAs in
ccRCC by initially detecting their expression levels in 10 matched
tumor-normal (adjacent) tissue pairs using the Illumina GA II
platform and then validating some of our most interesting findings
in a large cohort of ccRCC patients. Furthermore, network
analysis of the deregulated genes or the well annotated target genes
of the differentially expressed miRNAs pinpointed key signaling
and metabolic pathways that were frequently disrupted in most of
the investigated ccRCC patients.
Results
Overview of the DGE data generated in 10 ccRCCs
The expression levels of 17,595 protein-coding genes and 726
human miRNAs were determined to be detectable (at least one
transcript per million tags, 1 TPM) in at least one sample (either in
tumors or normal adjacent tissues) by our analysis pipeline. A total
of 404 distinct miRNAs and 9,799 mRNAs (Figure 1A) were
differentially expressed (P,0.01, FDR#0.001) in ccRCC samples
compared to the matched normal controls (see Table S1 and S2
for details), of which a large proportion was synchronously
upregulated or downregulated in at least two patients (Figure 1B).
Overall, the percentages of mRNA transcripts upregulated in each
individual ranged from 47.5 to 84.1% (average 64.3%), while
those for miRNAs ranged from 23.2% to 56.2% (average 35.3%).
In addition, 56 potentially novel miRNAs and 586 novel mRNA
expression tags were recurrently detected in at least two samples
(Tables S3 and S4). There were four novel candidates that were
only expressed at detectable levels in the tumor samples, while 40
of the novel miRNAs detectable in both tumor and normal tissues
displayed differential expression patterns (FDR #0.01) (Figure 1C
and Figure 1D).
Validation of the DGE analysis results using real-time
quantitative PCR (qPCR)
To validate the expression levels of the known miRNA and
mRNA genes determined by the DGE analysis, qPCR primers
were selectively designed for six miRNA and six mRNA genes
(Figure 2A and 2B), each of which was characterized by
concordant significant deregulation of its expression across all of
the tumor-normal tissue pairs profiled. The resulting validation
rates for all of the genes in individual patients ranged from 60% to
100%, with an average success rate of 88.3%. As illustrated in
Figure 2A and Figure 2B, the DGE results correlated well with the
qPCR results in terms of quantifying the expression of both
mRNAs and miRNAs. Additionally, 10 out of 14 of the predicted
miRNA candidates identified in at least two samples could be
successfully amplified by qPCR using miScript Reverse Tran-
scription and miScript SYBR Green PCR Kits (Qiagen,
Germany). Furthermore, the sequences of four out of five
randomly selected amplified products (hsa-Np-miR-02, hsa-Np-
miR-31, hsa-Np-miR-22, and hsa-Np-miR-15, see Table S3) were
confirmed by cloned Sanger sequencing (see Methods for details)
as predicted, indicating good accuracy of the DGE profiling in
identifying miRNAs (candidates) with no previously described
sequence or secondary structure information (Figure S1).
Deregulated expression of miRNAs and mRNAs in 10
ccRCCs
Consistent with recently published studies, the expression
profiles of protein-coding genes in ccRCC were characterized by
a loss of expression of most genes that are responsible for normal
renal function [21,22]. For instance, we observed that genes (such
as UMOD and AQP2) or gene families (SLC22A) involved in
regulating the homeostasis of water-electrolyte balances or
transepithelial transportation of toxic organic anions were most
significantly downregulated in ccRCCs [23,24]. In addition, other
well-known cancer-associated genes (including VEGFA, DUSP9
and ERBB4) were also selectively validated as exhibiting
consistently disrupted expression patterns in most of the ccRCC
samples profiled (Figure 2B). It should be noted that PNCK
(average log2Ratio =8.6) was ranked as the most highly
overexpressed gene in all of the tumors in our study.
Among the miRNAs that were most consistently downregulated
in the majority of ccRCCs, miR-184 and miR-206 (Figure 2A)
were previously reported to promote tumor cell apoptosis via
targeting key components in signal transduction pathways [25,26].
Additionally, consistent with what has been found in other studies
[27,28], miR-210 (a well-established miRNA gene that can be
induced under hypoxia conditions in many solid cancers in a HIF-
1a- and VHL-dependent manner) was also found to be significantly
overexpressed in all of the ccRCC samples in our study.
Paradoxically, though it was the most significantly upregulated
miRNA and was validated to be overexpressed nearly 25 fold on
average in all 10 of the ccRCCs sequenced, miR-122 has
predominately been demonstrated to be significantly downregu-
lated in hepatocellular carcinoma and to act as a negative
regulator of tumorigenesis [29]. Thus, full elucidation of the role of
miR-122 in ccRCC development beyond its well-known tumor-
suppressing function still awaits further study.
As listed in Table S5, a substantial number of miRNAs that were
recurrently up- or downregulated in the 10 ccRCCs also displayed
deregulated expression patterns in other cancers. The expression of
Integrated Profiling of miRNAs and mRNAs in ccRCC
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lymphoma [30], Hodgkin disease [31], CLL [32], AML [33], breast
cancer [34] and lung cancer [35]. The possible oncogenic effect of
miR-21 has also been reported in other solid cancers (including
pancreas, prostate, stomach, colon, lung and breast cancer) [36].
Our study also further confirmed the results presented by Liu et al.
that the loss of miR-200c expression results in gain of function of
VEGFA,and increasedlevelsofmiR-224causethelossoffunctionof
the tumor suppressor ERBB4 in ccRCC [18]. Furthermore, five
members of the miR-200 family (including miR-200c, miR-141,
miR-200a, miR-200b, and miR-429) were all significantly down-
regulated in the renal tumors sequenced. Recent studies revealed
that the miR-200 family may play a critical role in determining the
process of epithelial-to-mesenchymal transition (EMT), and that
Figure 1. Overview of the expression profiles of miRNAs and mRNAs in 10 ccRCC patients. A: The number of miRNAs and mRNAs
differentially expressed in 10 ccRCC patients (P,0.01, FDR#0.001). B: The number of miRNAs and mRNAs recurrently deregulated across 10 ccRCC
patients. One miRNA or mRNA may be deregulated only in partial of the 10 patients, and X-axis represents the at least case number, for example, the
column 2 represents the number of miRNAs or mRNAs deregulated in at least 2 patients. C: Venn diagram of putative novel miRNA candidates
identified in different tissues. D: Venn diagram of putative novel mRNA candidates identified in different tissues.
doi:10.1371/journal.pone.0015224.g001
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invasion and migration [37,38,39].
Pathway analysis of differentially expressed genes and
miRNA targets in ccRCC
Interconnected KEGG [40] pathways enriched in deregulated
genes were visualized with network-based approaches using
Cytoscape [41] with the ClueGo plug-in [42]. As shown in
Figure 3, multiple canonical cancer-associated signaling pathways
(Table S6), including focal adhesion, cell cycle and ECM-receptor
interaction, were significantly more likely to be disrupted in ccRCC
than expected by chance (FDR ,0.01). Various metabolic
pathways (such as those involved in amino acid metabolism) were
also observed to be enriched in deregulated genes in our study,
(FDR ,0.01). Generally, we observed that functionally interacting
pathways tended to exhibit similar deregulated expression patterns.
As has been found by other investigators, genes regulating cellular
signaling were more likely to be overexpressed, whereas metabolic
genes were predominantly downregulated in ccRCC [43].
All KEGG genes that were differentially expressed in at least
two patients were prioritized against each pathway by gene set
enrichment analysis (GSEA) [44,45] according to their expression
levels in all the samples. Core genes ranked at the top or bottom of
each pathway gene set were sorted using the leading edge analysis
method introduced by Subramanian A. Figure 4A provides a
reduced overview of the common core genes shared by multiple
pathways. Previously well-established cancer genes (including
PIK3CG, PIK3R3 and PIK3R5, EGFR, CCND1 and TP53), as well
as genes encoding key enzymes (ALDH1B1and ALDH2) were
predicted to play essential roles in ccRCC development based on
integrated pathway analysis.
Similarly, target genes of all of the miRNAs deregulated in at
least two ccRCCs were retrieved from two experimentally
supported databases, TarBase [46] and miRecords [47], for
subsequent pathway analysis. Multiple cancer-associated KEGG
pathways (e.g., cell cycle and p53 signaling) were found to be
enriched in the target genes regulated by miRNAs that were
recurrently deregulated in our study (Table S7). Furthermore, all
of the targets of recurrently deregulated miRNAs were tested
against a smaller pathway set: all 29 pathways catalogued under
the hierarchical designation of ‘pathways in cancer’ in the KEGG
database using GSEA. As shown in Figure 4B, miR-124 target
genes were implicated in the leading edge of 59 pathways,
including 9 pathways in cancer, followed by miR-155 (48
pathways, including 12 pathways in cancer) and miR-21 (37
pathways, including 14 pathways in cancer).
miRNA genes located on Xq27.3 significantly
downregulated in ccRCC
SevenmiRNAsofthemiR-506 family(miR-506,miR508-3pand
miR-509-5p, miR-509-3p, miR-509-3-5p, miR-510 and miR-514)
were clearly downregulated in most of the renal tumors sequenced
in the discovery screen. These miRNA genes were tandemly
clustered in the same genomic region, Xq27.3 (,8 Mb away from
the telomere). However, little information on the target genes
regulated by these miRNAs could be obtained from current
experimentally supported databases (TarBase and miRecords).
Nevertheless, as a pilot study, all 23 of the putative targets uniformly
predicted by miRanda [48] and miRNAMap [49] were evaluated
for their expression in the 10 ccRCCs. On average, all of these
targets were clearly upregulated in the tumors in comparison to
their matched controls. Predicted targets, such as VEGFB and
PSMA1 (regulated by miR-506), LDHA (regulated by miR-508-3p)
and HK1 (regulated by miR-509-3p), are core genes involved in
multiple key pathways. To further investigate the expression
patterns of the miRNA cluster found in the discovery screen, qPCR
tests were performed in matched pairs of cancer-normal adjacent
tissues in a large panel of ccRCC patients in the prevalence screen.
Asshown inFigure5,theexpression ofallof the testedmiRNAswas
significantly downregulated in the majority of the tumors screened.
In contrast, the expression levels of four predicted targets (HK1,
LDHA, PSMA1and VEGFB) were upregulated on average.
Discussion
DGE sequencing is a powerful and reliable tool for accurately
quantifying the absolute expression levels of both mRNAs and
Figure 2. Comparison of deep sequencing data and qPCR
results. For the comparison of deep sequencing data and qPCR results,
genes determined to be differentially expressed in all of the 10 patients
by deep sequencing were validated using qPCR. The height of the
columns in the chart represents the log-transformed average fold
change (tumor/normal) in expression across the 10 patients for each of
the genes validated; bars represent standard errors. A: The validation
results of six miRNAs indicated that the deep sequencing data were in
excellent agreement with the qPCR results. B: The validation results of
six mRNAs also indicated that the results of the deep sequencing were
generally agreed well with the qPCR results.
doi:10.1371/journal.pone.0015224.g002
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number of relatively high-abundance transcripts determined by
the availability of array probes [20]. The results of deep
sequencing correlated well with those of qPCR in our study based
on the validation results of randomly selected miRNA and mRNA
genes. In addition, the novel miRNA candidates identified in this
study, especially those validated by qPCR and Sanger sequencing,
further complements the current human miRNA catalog.
The most significantly downregulated gene in ccRCC in
comparison to normal tissue was the pregnancy-up-regulated
non-ubiquitously expressed CaM kinase gene (PNCK). PNCK was
previously found to be overexpressed in a particular subtype of
epithelial cells involved in the differentiation and transformation of
breast cancer [50]. A recent report also revealed that PNCK
mediates the protea-lysosomal degradation of EGFR protein and
may represent a promising target for therapeutic intervention in
EGFR-regulated oncogenesis [51]. Here, we report its possible
association with the development or progression of ccRCC for the
first time, though the molecular mechanisms underlying this
association remain largely unknown. Other well-known oncogenes
that control the cell division cycle, such as CDCA2 and CDKN2A,
were also likely to play crucial roles in the development of ccRCC,
as they were ranked at the top of the lists of genes that were highly
overexpressed in most ccRCCs in this study.
Our study highlights the importance of investigating the
functional roles of miRNAs in the tumorigenesis of ccRCC. Of
the minority (35.3%) of miRNAs that were most significantly
upregulated in the tumor tissues, the outlier miR-122 was initially
identified as a tumor-suppressor in other cancers [52,53],
indicating the necessity for the intensive investigation of well-
known cancer-associated miRNAs in different kinds of tumors for
full elucidation of their functional roles in tumorigenesis. Cellular
adaptation to hypoxic microenvironments is a characteristic of
many solid cancers [54]. Genetic inactivation of the VHL gene,
which regulates the ubiquitin-ligated degradation of hypoxia-
inducible factors (HIFs), has frequently been reported as the
‘‘driving event’’ initiating ccRCC [55]. Accumulation of HIF-1a at
the protein level leads to continuous activation of downstream
target genes (e.g., VEGF and PDGF), which were all upregulated in
our tumor sample panel [56,57]. Interestingly, miR-21, one of the
few currently known miRNA genes under the control of the VHL-
HIF-1a cascade, was also found to be significantly overexpressed in
ccRCC. It can be speculated that characterization of the miRNA
genes targeted by the VHL-HIF cascade, or the protein-coding
genes targeted by the VHL-HIF-miRNA cascade would be of great
value in furthering our understanding of the pathogenic
mechanisms underlying ccRCC.
It has become widely acknowledged that disrupted pathways, as
opposed to deregulated individual gene, drive the tumorigenesis
process [58]. Network-based pathway analysis of significantly
deregulated protein-coding genes allowed us to obtain an overview
of key pathways that may have profound effects on ccRCC
development. Core genes common to multiple pathways are more
likely to be cancer genes. As shown in Figure 4A, most of the genes
ranked in the top 20 of the final core gene sets determined by
GSEA have previously been causatively linked with tumorigenesis
in other studies, indicating a high predictive value of this
integrative pathway analysis in identifying genuine cancer genes
in ccRCC using our sequencing data. Similarly, all significantly
deregulated miRNA genes were also prioritized based on
Figure 3. Network analysis of differentially expressed pathways. Nodes in the network represent individual pathways, and edges in the
pathway represent the functional relationships between pathways. Pathways significantly enriched with more up- or downregulated genes are
represented in red or green, respectively. The color gradient of each node is proportional to the percent of genes up- or downregulated in each
pathway. In particular, if there are equal numbers of genes up- and downregulated in a pathway, the node representing the pathway is colored
white. The node size reflects the relative degree of significance to which the pathway is enriched in deregulated genes within the interconnected
subnetwork. In other words, larger nodes are expected to play more important roles in the interconnected pathway subnetwork. In addition, if a
pathway is significantly enriched with differentially expressed genes (corrected P-value ,0.05), the name of the pathway is highlighted in red (see
Table S7 for details).
doi:10.1371/journal.pone.0015224.g003
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experimentally supported databases. miR-155, miR-21, miR-34a,
miR-135a and miR-135b were previously found to be associated
with ccRCC [12,18,59], indicating that they are authentic cancer-
associated miRNAs in ccRCC. miR-155 and miR-21 were also
reported to be involved in the development of different cancers
[30,31,32,33,34,35,36]. In summary, in addition to the miRNA
and mRNA genes known to implicate in cancer development,
other genes prioritized at the top of our core gene list are
promising candidates worthy of further investigation.
It has been proposed that most of the known miRNAs are
tandemly clustered [60,61] and are transcribed as polycistronic
primary transcripts [62]. Positional enrichment analysis of the
deregulated miRNA genes revealed that the expression levels of the
miRNAs clustered at the fragile site Xq27.3 [63] were significantly
decreased in our study samples. Interestingly, careful analysis of the
results of another small sample study on ccRCC also revealed that
fiveof the seven miRNAs were downregulated in tumor tissues [64].
However, little attention has been paid to identifying the target
genes regulated by these miRNAs using classic molecular biology
methods. In the prevalence screen conducted in this study, the
deregulated expression patterns detected in ,50 ccRCC patients
for five of the miRNAs further supported the finding that the
miRNA genes located on Xq27.3 were expressed at substantially
lower levels in at least 76.7% of primary ccRCCs compared to
patient-matched normal adjacent controls. The high prevalence of
Figure 4. Pathway-based gene set enrichment analyses of differentially expressed mRNAs or miRNAs. Protein-coding genes were
ranked according to the number of pathways in which they were prioritized as core genes (most significantly deregulated genes). miRNAs were
ranked according to the number of pathways in which their target genes were prioritized as core genes. Columns in green/red represent the genes or
miRNAs that were down/upregulated on average in at least two ccRCCs respectively; columns in black represent the genes or miRNA targets involved
in at least one cancer-associated pathway. The height of the columns in different colors represents the number of pathways where the genes or
miRNA targets were ranked as core genes. A: Genes ranked in the top 20 based on the results of pathway-based gene set enrichment analysis. B:
miRNAs ranked the top 20 based on the results of pathway-based gene set enrichment analysis of their target genes.
doi:10.1371/journal.pone.0015224.g004
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expression of the miRNAs clustered at Xq27.3 is an important
event in ccRCC pathogenesis, and more detailed studies are needed
to establish their exact functional roles in carcinogenesis.
In summary, this is one of the few studies that have
simultaneously profiled the expression patterns of both miRNAs
and mRNAs on a genome-wide scale in ccRCC patients using
second-generation sequencing technology. Our results demon-
strated that the expression phenotype of ccRCC is characterized
by a loss of normal renal function, downregulated expression of
metabolic genes, and upregulation of many signal transduction
genes in key pathways. Individual pathway enrichment analysis
revealed that well-known cancer pathways (e.g., cell cycle,
apoptosis, focal adhesion and ECM-receptor interaction) play
critical roles in ccRCC development. With the aid of currently
available databases, we found that cancer-associated mRNA and
miRNA genes could be accurately prioritized with the integrative
pathway analysis approach using our sequencing data. Finally, we
also established the association of a cluster of miRNA genes on
Xq27.3 with ccRCC in a large sample set.
Materials and Methods
Clinical sample collection
All of the ccRCC tissues and matched normal adjacent tissues
used in this study were obtained from the clinical institutions of
Urinogenital Cancer Genomics Consortium (UGCC) in China.
Detailed information on the 10 patients sequenced in the discovery
screen is summarized in Table S8. Specimens were snap-frozen in
liquid nitrogen or deposited in RNALater (Qiagen, Germany) and
subsequently stored at 280uC. Hematoxylin-eosin (HE)-stained
sections were examined for tumor cell percentage, and tumor
tissues containing more than 80% tumor cells were selected for
further study. The matched normal adjacent tissues were defined
as kidney tissues located 2.0 cm outside of visible ccRCC lesions.
Histopathologic examination of the normal tissues indicated the
presence of normal renal tubules and glomeruli without tumor cell
contamination (Figure S2). The collection and use of the patient
samples were reviewed and approved by Institutional Ethics
Committees, and written informed consent from all patients was
appropriately obtained.
RNA extraction
Total RNA was extracted from ccRCC and normal adjacent
tissues using TRIZOL (Invitrogen, US) according to the
manufacture’s protocol and evaluated using Agilent 2100
Bioanalyzer (Agilent Technologies, US).
Digital gene expression (DGE) sequencing of mRNA and
statistical analysis
Of the total RNA isolated from each sample, 4 mg was used in
DGE sequencing. Briefly, following synthesis of double-stranded
cDNA using oligo(dT)18 beads, the cDNA was digested with NlaIII
and ligated to a first adapter (GEX adapter 1) containing a
restriction site recognized by MmeI. After dephosphorylation with
alkaline phosphatase CIAP, the purified MmeI-digested products
were linked to a second adapter (GEX index adapter) containing
2-bp degenerate 39 overhangs. Then, the double adapter-flanked
tags from the mRNAs were amplified by PCR using Phusion DNA
polymerase and Gex PCR primers following the manufacturer’s
protocol. PCR was carried out using the following program: 98uC
for 30 sec, followed by 15 cycles of 98uC for 10 sec, 60uC for
30 sec and 72uC for 15 sec, and then 72uC for 10 min. The
resulting ,85-bp PCR products were ethanol precipitated and
purified from electrophoresis gels using Spin-X filter columns.
Finally, mRNA libraries were sequenced on the Illumina Cluster
Station and Genome Analyzer II (Illumina Inc, USA) following the
manufacturer’s protocol.
Before statistical analysis, potentially erroneous tags (single copy
tags and tags consisting of adapter sequences or containing
unknown sequences ‘N’) were filtered out. All of the 17-bp
sequences next to the possible Nla III restriction sites in a human
reference genome (hg19) and the 4-bp CATG restriction enzyme-
digested site were extracted and concatenated as a new reference
[65]. Tags were mapped to the constructed reference using SOAP
V2.0 [66] allowing no more than one base mismatch. Only unique
mapping tags were used for gene expression analysis. Standardized
TPM (transcripts per million clean tags) values were applied to
compare gene expression between tumors and normal adjacent
tissues. The expression fold change (tumor versus normal) for each
gene was calculated as the log2Ratio using TPM values.
Subsequently, we performed a rigorous significance test to
determine the differentially expressed genes [67]. The resulting
P-values for all genes were corrected for multiple tests using a FDR
(false discovery rate) adjustment [68]. In addition, after filtering
out all annotated mRNA tags and those tags matching the
mitochondrial genome, the remaining clean tags that could be
mapped to the human reference genome were identified as
potentially novel mRNA expression tags. Only those tags
expressed in at least two samples at detectable levels ($1 TPM)
were defined as high-confidence novel mRNA expression tags.
DGE miRNA sequencing and statistical analysis
For miRNA sequencing, 5 mg of total RNA form each sample
was ligated with both a 59 adapter and 39 adapter for reverse
transcription using Superscript II at 42uC for 1 h and 70uCf o r
15 min. Subsequently, the reverse transcribed products were
amplified using the following PCR program: a 15-cycle reaction
at 98uC for 30 sec, followed by 15 cycles of 98uCf o r1 0s e c ,
Figure 5. qPCR results for five miRNAs clustered on Xq27.3 and
their putative target genes in ,50 ccRCC patients. The
expression of five miRNAs clustered on Xq27.3, as well as the expression
of some of their most interesting predicted targets was evaluated in a
large sample panel. The height of the columns in the chart represents
the log-transformed average fold change (tumor/normal) in expression
across all patients for each of the genes validated; bars represent the
standard errors. The number of samples (n) used in the validation assay
is shown beside each standard error bar. Generally, miRNAs were
downregulated in 76.7% to 88.6% of the patients, while the target
genes were upregulated in 63.8% to 84.9% of the patients.
doi:10.1371/journal.pone.0015224.g005
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,92-bp DNA band on 6% PAGE gels, the PCR products were
ethanol precipitated and purified using Spin-X filter columns.
Finally, miRNA libraries were sequenced on the Illumina Cluster
Station and Genome Analyzer II following the manufacturer’s
protocol.
Low quality reads were trimmed and adapter sequences were
accurately clipped with the aid of a dynamic programming
algorithm before subsequent statistical analysis. After elimination
of the duplicate reads, the remaining reads of at least 18 nt
were mapped to a human reference genome (hg19) using SOAP
V2.0. To remove tags originating from protein-coding genes,
repeat sequences, rRNA, tRNA, snRNA, and snoRNA, we
also mapped the short read tags to UCSC RefGene, RepeatMas-
ker and NCBI Refseq, as well as our in-house ncRNA annotation
datasets compiled from the NCBI GenBank database (http://
www.ncbi.nih.gov). The same pipeline used for DGE mRNA
differential expression analysis was also used for miRNA
expression analysis.
Prediction of novel miRNA candidates and determination
of miRNA target genes
Mireap (http://sourceforge.net/projects/mireap) was used to
predict novel miRNA candidates based on their secondary
structure, stability of their hairpin structure and the Dicer cleavage
site of the miRNA tags. Moreover only those candidates fulfilling
the following two criteria were defined as high-confidence miRNA
candidates in our study: 1) stable hairpin structure with low free
energy (,220 kcal/mol); 2) expressed in at least two samples at
detectable levels (1 TPM).
miRNA target genes that were supported by two databases
(TarBase and miRecords) with experimental evidence were
retrieved for pathway analysis. For those miRNAs (clustered on
Xq27.3) without target recorded in the two databases mentioned
above, we only retained those putative targets uniformly predicted
by miRanda and miRmap 2.0.
Pathway analysis of differentially expressed genes and
miRNAs
KEGG pathway analysis was performed the using Cytoscape
V2.6.3 (http://cytoscape.org/) with the ClueGo plug-in. Right-
side hypergeometric tests were used to identify pathways enriched
in deregulated genes. Benjamini-Hochberg adjustment was
applied for multiple test correction. Differentially expressed genes,
as well as target genes of deregulated miRNAs were mapped onto
KEGG pathways for network construction.
All KEGG genes that were differentially expressed in at least
two patients were prioritized against each pathway by gene set
enrichment analysis (GSEA) according to their expression levels in
all of the samples. Core genes or miRNA targets ranked at the top
or bottom of each pathway gene list were most significantly altered
between tumors and normal adjacent tissues (called leading edge
in GSEA). An individual gene or miRNA target may be implicated
in the leading edge of multiple pathways, and the numbers of
pathways in which the core genes or miRNAs were implicated
were determined by the leading edge analysis. In addition, to
further reveal the roles of miRNAs and genes in ccRCC, we
subsequently constructed a dataset based on all 29 pathways
catalogued under the hierarchical designation of ‘pathways in
cancer’ (ko05200) in the KEGG database for GSEA. miRNAs and
genes ranked in the leading edge of these cancer-associated
pathways may play more important roles than others in
tumorigenesis.
Validation of the expression of miRNAs and mRNAs by
qPCR
To validate the expression levels of the known miRNA and
mRNA genes determined by deep sequencing, qPCR primers
were selectively designed for six miRNA and six mRNA genes. Six
genes (VEGFA, YWHAH, DUSP9, NR4A1, HSPA2 and ERBB4) that
were differentially expressed in all patients in the discovery screen
were validated in both tumor and normal adjacent tissues from the
10 ccRCC patients using qPCR. b-actin was selected as the
internal control. In brief, 2 mg of total RNA from each sample was
reverse transcribed for cDNA synthesis using a reverse transcrip-
tion kit according to the manufacturer’s protocol (Promega,
Madison, WI). The reverse transcription products were amplified
using the following PCR program: 94uC for 4 min, followed by 30
cycles of 94uC for 30 sec, 55uC for 30 sec, 72uC for 30 sec and
then extension at 72uC for 10 min. Six miRNAs (miR-122, miR-
210, miR-184, miR-206, miR-660 and miR-502-3p) that were
deregulated in all patients were also selected for validation by
qPCR using the miScript Reverse Transcription and miScript
SYBR Green PCR Kits according to the manufacturer’s protocol
(Qiagen, Germany) and snRNA U6 was used as the internal
control. PCR was performed for both tumor and normal tissue
samples using the following program: 95uC for 15 minutes,
followed by 40 cycles of 94uC for 15 sec, 55uC for 30 sec and
72uC for 30 sec.
The expression levels of miR-509-5p, miR508-3p, miR-514,
miR-509-3-5p and miR-509-3p, as well as their putative target
genes (PSMA1, LDHA, HK1 and VEGFB) were evaluated in both
the tumor and normal adjacent tissues obtained from ,50 ccRCC
patients by qPCR. The PCR programs and reverse transcription
kits used were as mentioned above.
We randomly selected 14 novel miRNAs candidates for
validation by qPCR. Briefly, after adding poly(A) to the end
of mature miRNAs with poly(A) polymerase, reverse-transcrip-
tion was performed using oligo-dT and random primers.
Using the resulting cDNA products as templates, real-time
PCR was performed with miRNA-specific primers and uni-
versal primers provided by the miScript SYBR Green PCR
Kit. The purified qPCR products excised from agarose gels
were cloned into the PMD18-T vector (TAKARA, Dalian,
China) for subsequent sequencing on an AB 3730 DNA
analyzer. All of the primers used in the validation assays are
listed in Table S9.
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